Photo of { Punam Malik, MD}

Punam Malik, MD


  • Director, Cincinnati Comprehensive Sickle Cell Center
  • Program Leader, Hematology and Gene Therapy Program
  • Marjory J. Johnson Chair, Gene and Cell Therapy
  • Professor, UC Department of Pediatrics

About

MBBS: University of Delhi, New Delhi, India, 1985

MD: University of Delhi, New Delhi, India, 1989

MS: University of Maryland, Baltimore, MD, 1991

Fellowship: Children's Hospital Los Angeles, University of Southern California, 1995

Research Areas

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Cure Sickle Cell Initiative recommendations on common data elements for sickle cell disease gene therapy trials. Lanzkron, S; Coleman-Cowger, VH; Thompson, AA; Carroll, CP; Clemons, T; Debaun, M; Kanter, J; Malik, P; Manwani, D; Pierciey, FJ; Walters, MC; Alai, S. Blood advances. 2026; 10(11):3960-3965.

Renin-Angiotensin-Aldosterone System Inhibition Exacerbates Anemia in Sickle Cell Disease. Eskandari, N; Pappano, E; Ruiz, MAD; Mahmud, N; Ren, G; Ivy, ZK; Gaitonde, S; Gordeuk, VR; Gladwin, MT; Malik, P; Quinn, CT; Saraf, SL. Blood. 2026.

Angiotensin signaling is essential for stress erythropoiesis but causes retention of dysfunctional mitochondria in RBCs. Rai, P; Roy, S; Arumugam, P; Konstantinidis, DG; Ponny, SR; Eiymo Mwa Mpollo, M-S; Shrestha, A; Kalfa, TA; Malik, P. JCI Insight. 2026; 11(9).

Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview. Kassim, AA; Thompson, AA; Malik, P. American Journal of Hematology. 2026; 101 Suppl 1(Suppl 1):56-74.

Longitudinal changes and predictors of cardiac extracellular volume fraction in sickle cell anemia. Niss, O; Morin, CE; Hashemi, S; Alsaied, T; Lang, SM; Taylor, MD; Tasset, M; Malik, P; Quinn, CT. Blood Red Cells Iron. 2025; 1(3).

Replicative stress-induced aging of hematopoietic stem progenitor cells increases oncogenic mutation burden and incidence of myelodysplasia in sickle cell disease mice. Chi, M; Lucas, F; Husami, A; Setayesh, T; Zhu, Z; Kaur, H; Tijani, A; Khanal, S; Chen, J; Zhang, W; Malik, P. Blood. 2025; 146(Supplement 1):11.

Renin-angiotensin-aldosterone system inhibitors exacerbate anemia in sickle cell disease. Pappano, E; Eskandari, N; Ruiz, MA; Ren, G; Zhang, X; Han, J; Ivy, Z; Njoku, F; Farooqui, M; Molokie, R; Gordeuk, V; Gladwin, M; Malik, P; Quinn, C; Saraf, S. Blood. 2025; 146(Supplement 1):297-297.

Oxidative stress and hemoglobin-c denaturation drive hemoglobin SC pathophysiology and can be ameliorated by antioxidants and hydroxyurea. Setayesh, T; Tijani, A; Kaur, H; Khanal, S; Zhu, Z; Chi, M; Kincaid, A; Ware, R; Malik, P. Blood. 2025; 146(Supplement 1):7.

Impact of disease genotype and severity of anemia on myocardial extracellular volume fraction in sickle cell disease (SCD) and non-SCD hemolytic anemias. Niss, O; Morin, C; Hashemi, S; Alsaied, T; Lang, S; Tasset, M; Taylor, M; Malik, P; Quinn, C. Blood. 2025; 146(Supplement 1):2957.

A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea. Setayesh, T; Chi, M; Oestreicher, Z; Sakabe, M; Seu, K; Zhu, Z; Kaur, H; Tijani, A; Xin, M; Shova, A; Balla, J; Vandenheuvel, K; Hu, Y-C; Malik, P. Blood. 2025; 146(1):13-28.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey

Loading ...
Loading ...